The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Open accessAbstract
Conventional radiotherapy, in addition to its well-established tumoricidal effects, can also activate the host immune system. Radiation therapy modulates tumour phenotypes, enhances antigen presentation and tumour immunogenicity, increases production of cytokines and alters the tumour microenvironment, enabling destruction of the tumour by the immune system. Investigating the combination of radiotherapy with immunotherapeutic agents, which also promote the host antitumour immune response is, therefore, a logical progression. As the spectrum of clinical use of stereotactic radiotherapy continues to broaden, the question arose as to whether the ablative radiation doses used can also stimulate immune responses and, if so, whether we can amplify these effects by combining immunotherapy and stereotactic ablative radiotherapy (SABR). In this Perspectives article, we explore the preclinical and clinical evidence supporting activation of the immune system following SABR. We then examine studies that provide data on the effectiveness of combining these two techniques — immunotherapy and SABR — in an approach that we have termed 'ISABR'. Lastly, we provide general guiding principles for the development of future clinical trials to investigate the efficacy of ISABR in the hope of generating further interest in these exciting developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Self-citationDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70168-3 · Cited by 1,462
Self-citationLee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Maximizing Tumor Immunity With Fractionated Radiation
Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.049 · Cited by 567
Said, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J., Noto, A., Ancuta, P., Peretz, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2106 · Cited by 481
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Senthi, S., Lagerwaard, F. J., Haasbeek, C. J., Slotman, B. J., & Senan, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70242-5 · Cited by 447
Gameiro, S. R., Jammeh, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1719 · Cited by 415
Self-citationKiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 390
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
A Sense of Danger from Radiation1
McBride, W. H., Chiang, C.-S., Olson, J. L., Wang, C.-C., Hong, J.-H., Pajonk, F., Dougherty, G. J., Iwamoto, K. S., Pervan, M., & Liao, Y.-P. (2004) · Radiation Research · doi:10.1667/rr3196 · Cited by 323
Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
Formenti, S. C., & Demaria, S. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.06.020 · Cited by 319
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
Seung, S. K., Curti, B. D., Crittenden, M., Walker, E., Coffey, T., Siebert, J. C., Miller, W., Payne, R., Glenn, L., Bageac, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003649 · Cited by 303
Radiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
Estimating the mutation load in human genomes
Henn, B. M., Botigué, L. R., Bustamante, C. D., Clark, A. G., & Gravel, S. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3931 · Cited by 281
Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K., Ferrone, S., & Gameiro, S. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28070 · Cited by 281
Self-citationIpilimumab and radiation therapy for melanoma brain metastases
Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013) · Cancer Medicine · doi:10.1002/cam4.140 · Cited by 280
The oligometastatic state—separating truth from wishful thinking
Palma, D. A., Salama, J. K., Lo, S. S., Senan, S., Treasure, T., Govindan, R., & Weichselbaum, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.96 · Cited by 277
Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., & Knox, S. J. (2012) · Translational Oncology · doi:10.1593/tlo.12280 · Cited by 247
Shirvani, S. M., Jiang, J., Chang, J. Y., Welsh, J., Likhacheva, A., Buchholz, T. A., Swisher, S. G., & Smith, B. D. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2014.556 · Cited by 245
Self-citationExpression of MAGE-antigens in normal tissues and cancer
Jungbluth, A. A., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Chen, Y.-T., Spagnoli, G. C., & Old, L. J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000215)85:4<460::aid-ijc3>3.0.co;2-n · Cited by 217
Kotera, Y., Shimizu, K., & Mulé, J. J. (2001) · PubMed · Cited by 204
Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Friedman, E. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394089 · Cited by 201
Chen, Z., Moyana, T. N., Saxena, A., Warrington, R. C., Jia, Z., & Xiang, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1365 · Cited by 165
Chang, J. Y., Liu, H., Balter, P. A., Komaki, R. R., Liao, Z. X., Welsh, J. W., Mehran, R. J., Roth, J. A., & Swisher, S. G. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-152 · Cited by 148
Self-citationHodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., & Gameiro, S. R. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.006 · Cited by 145
Self-citationImmune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Gulley, J. L., Madan, R. A., Tsang, K. Y., Jochéms, C., Marté, J. L., Farsaci, B., Tucker, J. A., Hodge, J. W., Liewehr, D. J., Steinberg, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0108 · Cited by 141
Self-citationCurrent Clinical Trials Testing Combinations of Immunotherapy and Radiation
Crittenden, M. R., Kohrt, H. E. K., Levy, R., Jones, J. C., Camphausen, K. A., Dicker, A. P., Demaria, S., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.003 · Cited by 135
The role of stroma in immune recognition and destruction of well-established solid tumors
Yu, P., Rowley, D. A., Fu, Y., & Schreiber, H. W. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.004 · Cited by 124
Hodge, J. W., Sharp, H. J., & Gameiro, S. R. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1202 · Cited by 119
Self-citationApoptosis or necrosis for tumor immunotherapy: what's in a name?
Melcher, A. A., Gough, M. J., Todryk, S. M., & Vile, R. G. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900066 · Cited by 114
Kwilas, A. R., Donahue, R. N., Bernstein, M. B., & Hodge, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00104 · Cited by 107
Self-citationRadiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Zegers, C. M. L., Rekers, N. H., Quaden, D. H. F., Lieuwes, N. G., Yaromina, A., Germeraad, W. T. V., Wieten, L., Biessen, E. A. L., Boon, L., Neri, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2676 · Cited by 99
Timmerman, R. D., Paulus, R., Pass, H. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.7523 · Cited by 99
Chang, J. Y., Liu, Y., Zhu, Z., Welsh, J. W., Gomez, D. R., Komaki, R., Roth, J. A., & Swisher, S. G. (2013) · Cancer · doi:10.1002/cncr.28217 · Cited by 91
Bernstein, M. B., Garnett‐Benson, C., Zhang, H., Velcich, A., Wattenberg, M. M., Gameiro, S. R., Kalnicki, S., Hodge, J. W., & Guha, C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1578 · Cited by 87
Self-citationImaizumi, N., Monnier, Y., Hegi, M. E., Mirimanoff, R., & Rüegg, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011084 · Cited by 80
The dendritic cell–tumor cross-talk in cancer
Ma, Y., Aymeric, L., Locher, C., Kroemer, G., & Zitvogel, L. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.09.008 · Cited by 80
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 78
Self-citationGameiro, S. R., Caballero, J. A., Higgins, J. P., Apelian, D., & Hodge, J. W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1020-8 · Cited by 77
Self-citationKwek, S. S., Dao, V. A., Roy, R., Hou, Y., Alajajian, D., Simko, J. P., Small, E. J., & Fong, L. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201529 · Cited by 69
An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
Zhang, H., Liu, L., Yu, D., Kandimalla, E. R., Sun, H. B., Agrawal, S., & Guha, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038111 · Cited by 66
Bolli, M., Kocher, T., Adamina, M., Güller, U., Dalquen, P., Haas, P., Mirlacher, M., Gambazzi, F., Harder, F. H., Heberer, M., et al. (2002) · PubMed Central · doi:10.1097/01.sla.0000036266.09823.6c · Cited by 63
Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen Expression
Bolli, M., Kocher, T., Adamina, M., Güller, U., Dalquen, P., Haas, P., Mirlacher, M., Gambazzi, F., Harder, F. H., Heberer, M., et al. (2002) · Annals of Surgery · doi:10.1097/00000658-200212000-00011 · Cited by 57
Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu347.1 · Cited by 54
Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells
Aryankalayil, M. J., Makinde, A. Y., Gameiro, S. R., Hodge, J. W., Rivera-Solis, P. P., Palayoor, S. T., Ahmed, M. M., & Coleman, C. N. (2014) · Radiation Research · doi:10.1667/rr13731.1 · Cited by 50
Self-citationDisis, M. L., Dang, Y., Coveler, A. L., Marzbani, E., Kou, Z. C., Childs, J. S., Fintak, P. A., Higgins, D. M., Reichow, J. L., Waisman, J. R., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1489-4 · Cited by 37
Cited by
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“[100] Additionally, DNA damage by radiotherapy is able to induce the expression of NKG2D ligands on tumour cells, [101,102] which may promote activation of NK cells and enhance their cytotoxicity against tumour cells.”
BackgroundMetformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Metadata
- Authors
- Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-03-08
- Volume
- 13
- Issue
- 8
- Pages
- 516-524
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2293494611
- Cited by
- 399
- References
- 64
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.